Aurinia Pharmaceuticals Inc. (AUPH) NASDAQ
15.39
+0.08(+0.52%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Aurinia Pharmaceuticals Inc.
Address
4464 Markham Street
Edmonton, BC V8Z 7X8
Canada
Phone
12507084272
Sector
Healthcare
Industry
Biotechnology
Employees
130
First IPO Date
September 03, 2014
Key Executives
| Name | Title | Pay | Year Born |
| Kevin C. Tang | Chairman & CEO | 0 | 1967 |
| Gregory F. Keenan | Senior VP & Chief Medical Officer | 779,114 | 1962 |
| Michael S. Hearne | Chief Financial Officer | 866,870 | 1963 |
| Stephen Robertson | Chief Legal Officer, Corporate Secretary & Chief Compliance Officer | 923,480 | 1982 |
| Peter S. Greenleaf | Consultant | 1.7M | 1970 |
| Michael Gammons | Vice President & Chief Information Officer | 0 | N/A |
| Ryan Cole | Chief Operating Officer | 0 | 1987 |
| Stewart Kroll | Chief Development Officer | 0 | 1959 |
| Thomas Wei | Chief Scientific Officer | 0 | 1976 |
| Andrea Levin Christopher | Executive Director of Corporate Communications & Investor Relations | 0 | N/A |
| Eric Victory | Vice President of Corporate Development | 0 | N/A |
| Richard Lewis | Vice President of Sales | 0 | N/A |
Description
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.
